Financial reports
ARS
2023 FY
Annual report to shareholders
25 Apr 24
10-K
2023 FY
Annual report
14 Mar 24
10-Q
2023 Q3
Quarterly report
8 Nov 23
10-Q
2023 Q2
Quarterly report
28 Aug 23
10-K/A
2022 FY
Annual report (amended)
28 Aug 23
NT 10-Q
Notice of late quarterly filing
10 Aug 23
10-Q
2023 Q1
Quarterly report
8 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
10-K
2022 FY
Annual report
10 Mar 23
10-Q
2022 Q3
Quarterly report
3 Nov 22
Current reports
8-K
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
23 Apr 24
8-K
Entry into a Material Definitive Agreement
16 Apr 24
8-K
Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis
27 Mar 24
8-K
Departure of Directors or Certain Officers
15 Mar 24
8-K
Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
14 Mar 24
8-K
Departure of Directors or Certain Officers
13 Feb 24
8-K
Entry into a Material Definitive Agreement
30 Jan 24
8-K
Departure of Directors or Certain Officers
8 Jan 24
8-K
Results of Operations and Financial Condition
8 Jan 24
8-K
Entry into a Material Definitive Agreement
18 Dec 23
Registration and prospectus
S-8
Registration of securities for employees
30 Jan 24
S-8
Registration of securities for employees
6 Jun 23
S-8
Registration of securities for employees
30 Jan 23
424B5
Prospectus supplement for primary offering
7 Apr 22
424B5
Prospectus supplement for primary offering
7 Apr 22
POS AM
Prospectus update (post-effective amendment)
1 Mar 22
POSASR
Automatic shelf registration (post-effective amendment)
1 Mar 22
S-8
Registration of securities for employees
28 Jan 22
S-3ASR
Automatic shelf registration
25 Feb 21
S-8
Registration of securities for employees
22 Jan 21
Proxies
DEFA14A
Additional proxy soliciting materials
25 Apr 24
DEF 14A
Definitive proxy
25 Apr 24
DEF 14A
Definitive proxy
28 Apr 23
DEFA14A
Additional proxy soliciting materials
21 Apr 23
DEFA14A
Additional proxy soliciting materials
14 Apr 23
DEFA14A
Additional proxy soliciting materials
14 Apr 23
DEFA14A
Additional proxy soliciting materials
11 Apr 23
DEFA14A
Additional proxy soliciting materials
31 Mar 23
DEFA14A
Additional proxy soliciting materials
27 Mar 23
DEFA14A
Additional proxy soliciting materials
27 Mar 23
Other
CT ORDER
Confidential treatment order
13 Dec 22
CT ORDER
Confidential treatment order
7 Oct 22
EFFECT
Notice of effectiveness
29 Apr 22
CT ORDER
Confidential treatment order
18 Mar 22
CT ORDER
Confidential treatment order
30 Dec 21
CT ORDER
Confidential treatment order
25 Sep 20
CT ORDER
Confidential treatment order
15 Jul 20
CT ORDER
Confidential treatment order
12 Jun 20
CT ORDER
Confidential treatment order
24 Apr 20
UPLOAD
Letter from SEC
24 Apr 20
Ownership
4
Michel Dahan
1 Mar 24
4
Nicole R. Hadas
1 Mar 24
4
John P. Butler
1 Mar 24
4
Steven Keith Burke
1 Mar 24
4
Nicole R. Hadas
29 Feb 24
4
Michel Dahan
29 Feb 24
4
Steven Keith Burke
29 Feb 24
4
John P. Butler
29 Feb 24
144
Notice of proposed sale of securities
29 Feb 24
144
Notice of proposed sale of securities
29 Feb 24